Digoxin — 250MCG/ML, Injection, carton of 25 × 2 mL ampules

Digoxin — 250MCG/ML, Injection, carton of 25 × 2 mL ampules

Digoxin is a injection for intramuscular; intravenous use. Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Control of resting ventricular rate in adults with chronic atrial fibrillation. ( 1.3 ) 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms, as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality.

• Active ingredient or product type: DIGOXIN
• Strength/concentration: 250MCG/ML
• Dosage form and route: Injection, Intramuscular; Intravenous
• Exact package presentation: carton of 25 × 2 mL ampules
• NDC/item number: 0641-6184-25
• Manufacturer: HIKMA PHARMACEUTICALS USA INC
• Storage/handling: Store at 20˚ to 25˚C (68˚ to 77˚F), excursions permitted to 15˚to 30˚C (59˚ to 86˚F) [see USP Controlled Room Temperature]. Protect from light. Discard unused portion.
• Status: Rx only

Important safety information: Risk of rapid ventricular response leading to ventricular fibrillation in patients with AV accessory pathway. ( 5.1 ) Risk of advanced or complete heart block in patients with sinus node disease and AV block. ( 5.2 ) Digoxin toxicity: Indicated by nausea, vomiting, visual disturbances, and cardiac arrhythmias.

Refer to the current product labeling for complete indications, preparation or administration instructions, contraindications, warnings, precautions, and storage requirements.